Legend Biotech (LEGN) Research & Development (2019 - 2026)
Legend Biotech's (LEGN) quarterly Research & Development came in at $85.7 million in Q1 2026, down 15.9% YoY from $101.9 million in Q1 2025, and up 184.6% on a QoQ basis from -$101.3 million in Q4 2025.
Legend Biotech (LEGN) Research & Development (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Research & Development data on file, last reported at $85.7 million in Q1 2026.
- Quarterly Research & Development fell 15.9% year-over-year to $85.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$227.0 million (down 7.79% YoY) and the FY2025 annual result came in at -$414.7 million, changed 0.29% from the prior year.
- Research & Development improved to $85.7 million in Q1 2026, from -$101.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $101.9 million in Q1 2025 to a low of -$113.1 million in Q3 2025.
- A 5-year average of -$67.7 million and a median of -$95.8 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development sank 114639.98% — and 2025, when it jumped 200.93%.
- Tracing LEGN's Research & Development over 5 years: stood at -$80.8 million in 2022, then jumped by 99.87% to -$105683.0 in 2023, then slumped by 98685.99% to -$104.4 million in 2024, then advanced by 2.97% to -$101.3 million in 2025, then jumped by 184.6% to $85.7 million in 2026.
- The last three Research & Development figures came in at $85.7 million (Q1 2026), -$101.3 million (Q4 2025), and -$113.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 96.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 96.00 Mn |
| Mar 31, 2026 | 85.70 Mn |
| Dec 31, 2025 | -101.30 Mn |
| Sep 30, 2025 | -113.15 Mn |
| Jun 30, 2025 | -98.30 Mn |
| Mar 31, 2025 | 101.90 Mn |
| Dec 31, 2024 | -104.40 Mn |
| Sep 30, 2024 | -95.52 Mn |
| Jun 30, 2024 | -112.63 Mn |
| Mar 31, 2024 | -100.96 Mn |
| Dec 31, 2023 | -105,683.00 |
| Sep 30, 2023 | -95.86 Mn |
| Jun 30, 2023 | -95.79 Mn |
| Mar 31, 2023 | -84.89 Mn |
| Dec 31, 2022 | -80.76 Mn |
| Sep 30, 2022 | -104.52 Mn |
| Jun 30, 2022 | -68.83 Mn |
| Mar 31, 2022 | -81.55 Mn |
| Dec 31, 2021 | -86.50 Mn |
| Sep 30, 2021 | -72.31 Mn |